DIET-INDUCED METABOLIC SYNDROME DOES NOT AFFECT POSTISCHEMIC CONTRACTILITY OF THE RAT MYOCARDIUM

Highlights

• Diet-induced metabolic syndrome does not lead to mitochondrial respiration impairment and worsening of contractile dysfunction of the rat myocardium.
• Preservation of contractile function may be associated with substrate oxidation by complex II of the mitochondrial respiratory chain. It can be assumed that the initial metabolic changes of donors are not a significant obstacle to myocardial transplantation.

Abstract

Background. Tissue resistance to acute ischemia is an important problem of medical science in general and transplantology in particular. At the same time, carbohydrate and lipid metabolism disorders can cause a decrease in organ resistance to ischemia, and the high prevalence of such disorders in the population is an important problem for the preservation of the transplanted organ.

Aim. To assess the effect of experimental metabolic syndrome (MS) on the severity of myocardial contractile dysfunction during reperfusion, and the relationship between myocardial contractility in MS and mitochondrial respiration.

Methods. The study was performed on Wistar rats. Metabolic syndrome (MS) was modeled by feeding rats of a high-carbohydrate, high-fat diet for 12 weeks. Post-ischemic myocardial contractility was assessed using an in vivo model of acute coronary occlusion-reperfusion (ACR) echocardiography and an isolated heart ischemia-reperfusion model. Mitochondria were isolated by differential centrifugation from the ischemic zone after ACR. Mitochondrial respiration was assessed in the presence of malate, pyruvate, and succinate.

Results. Keeping rats on a diet for 12 weeks led to the formation of obesity, hypertension, increased blood glucose, triglyceride, leptin, and adiponectin levels, i.e., to the metabolic syndrome formation. Myocardial contraction parameters before ischemia modeling both in vivo and in the isolated heart model did not differ. Mitochondria of rats with MS were distinguished by greater efficiency of ADP/O respiration on both NAD+ and FAD+-dependent substrates.

ACR in vivo led to a decrease in the contractile and pumping function of the myocardium, suppression of mitochondrial respiration equally in the group of control animals and animals with MS. Similar data were obtained in the isolated heart model. An inverse correlation link was established between the efficiency of mitochondrial respiration in rats with MS in the presence of a FAD+-dependent substrate and the value of the end-systolic volume at late stages of reperfusion. Such a relationship was not observed in the control group rats.

Conclusion. The obtained results suggest that diet-induced MS does not lead to mitochondrial respiration impairment and aggravation of myocardial contractile dysfunction. Preservation of contractile function may be associated with oxidation of substrates by complex II of the mitochondrial respiratory chain. It can be assumed that the initial metabolic changes in donors are not a significant obstacle to myocardial transplantation.

1. Cruz C.B.B.V., Hajjar L.A., Bacal F., Lofrano-Alves M.S., Lima M.S.M., Abduch M.C., Vieira M.L.C., Chiang H.P., Salviano J.B.C., da Silva Costa I.B.S., et al. Usefulness of speckle tracking echocardiography and biomarkers for detecting acute cellular rejection after heart transplantation. Cardiovascular Ultrasound 2021; 19(1): 6. doi:10.1186/s12947-020-00235-w.

2. Martin S.S., Aday A.W., Allen N.B., Almarzooq Z.I., Anderson C.A.M., Arora P., Avery C.L., Baker-Smith C.M., Bansal N., Beaton A.Z., et al. 2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation 2025; 151(8): e41–660. doi:10.1161/CIR.0000000000001303.

3. Takeno M., Yasuda S., Otsuka Y., Morii I., Kawamura A., Yano K., Miyazaki S. Impact of Metabolic Syndrome on the Long-Term Survival of Patients With Acute Myocardial Infarction Potential Association With C-Reactive Protein. Circulation Journal 2008; 72(3): 415–9. doi:10.1253/circj.72.415.

4. Ege M.R., Guray U., Bøhmer E., Seljeflot I., Arnesen H., Hoffmann P., Abdelnoor M., Halvorsen S. Comment on: The association between metabolic syndrome and infarct size in patients with acute myocardial infarction. Scandinavian Journal of Clinical and Laboratory Investigation 2010; 70(8): 592–592. doi:10.3109/00365513.2010.481819.

5. Thim T., Bentzon J.F., Kristiansen S.B., Simonsen U., Andersen H.L., Wassermann K., Falk E. Size of myocardial infarction induced by ischaemia/reperfusion is unaltered in rats with metabolic syndrome. Clinical Science 2006; 110(6): 665–71. doi:10.1042/CS20050326.

6. Donner D., Headrick J.P., Peart J.N., Du Toit E.F. Obesity improves myocardial ischaemic tolerance and RISK signalling in insulin-insensitive rats. Disease Models & Mechanisms 2013; 6: 457–66. doi:10.1242/dmm.010959.

7. Naryzhnaya N.V., Birulina Yu.G., Kurbatov B.K., Sirotina M.A., Maslov L.N. Age-related features of developing insulin resistance and adipocyte sensitivity to insulin in rats with induced metabolic syndrome. Siberian Journal of Clinical and Experimental Medicine. 2021;36(3):119-126. doi:10.29001/2073-8552-2021-36-3-119-126. (In Russian)

8. Popov S.V., Mukhomedzyanov A.V., Maslov L.N., Naryzhnaya N.V., Kurbatov B.K., Prasad N.R., Singh N., Fu F., Azev V.N. The Infarct-Reducing Effect of the δ2 Opioid Receptor Agonist Deltorphin II: The Molecular Mechanism. Membranes 2023; 13(1): 63. doi:10.3390/membranes13010063.

9. Prokudina E.S., Naryzhnaya N.V., Mukhomedzyanov A.V., Gorbunov A.S., Zhang Y., Jaggi A.S., Tsibulnikov S.Y., Nesterov E.A., Lishmanov Y.B., Suleiman M.S.S., et al. Effect of Chronic Continuous Normobaric Hypoxia on Functional State of Cardiac Mitochondria and Tolerance of Isolated Rat Heart to Ischemia and Reperfusion: Role of µ and δ2 Opioid Receptors. Physiological Research 2019; 68(6): 909–20. doi:10.33549/physiolres.933945.

10. Clavijo L.C., Pinto T.L., Kuchulakanti P.K., Torguson R., Chu W.W., Satler L.F., Kent K.M., Suddath W.O., Pichard A.D., Waksman R. Metabolic syndrome in patients with acute myocardial infarction is associated with increased infarct size and in-hospital complications. Cardiovascular Revascularization Medicine 2006; 7(1): 7–11. doi:10.1016/j.carrev.2005.10.007.

11. Chen H.H., Wu C.J., Chen Y.C., Tsai C.S., Lin F.J., Yeh H.I. Metabolic syndrome is associated with severe coronary artery disease and poor cardiac outcome in end-stage renal disease patients with acute coronary syndrome. Coronary Artery Disease 2006; 17(7): 593–6. doi:10.1097/01.mca.0000224418.21563.6e.

12. Iglesias Bolaños P., Olivar Roldán J., Peñalver Talavera D., Díaz Guardiola P., Vega Piñero B., Monereo Megías S. Impacto de la obesidad central en la extensión del área de necrosis miocárdica. Endocrinología y Nutrición 2009; 56(1): 4–8. doi:10.1016/S1575-0922(09)70187-1.

13. Kranjčec D., Altabas V. Metabolic syndrome influencing infarct size and heart failure in patients with acute coronary syndrome - Does gender matter? Endocrine Journal 2012; 59(12): 1065–76. doi:10.1507/endocrj.EJ12-0131.

14. Islam M.S., Bari M.A., Paul G.K., Islam M.Z., Rahman M.Z., Hoshneara M., Karim M.A., Nabi M.N., Pandit H. Impact of metabolic syndrome in acute myocardial infarction at hospital. Mymensingh Medical Journal : MMJ 2013; 22(2): 261–6.

15. Traub J., Schürmann P., Schmitt D., Gassenmaier T., Fette G., Frantz S., Störk S., Beyersdorf N., Boivin-Jahns V., Jahns R., et al. Features of metabolic syndrome and inflammation independently affect left ventricular function early after first myocardial infarction. International Journal of Cardiology 2023; 370: 43–50. doi:10.1016/j.ijcard.2022.10.142.

16. Hajsadeghi S., Chitsazan M., Chitsazan M., Haghjoo M., Babaali N., Norouzzadeh Z., Mohsenian M. Metabolic syndrome is associated with higher wall motion score and larger infarct size after acute myocardial infarction. Research in Cardiovascular Medicine 2015; 4(1): 3. doi:10.5812/cardiovascmed.25018.

17. Zhao L.-H., Liu Y., Xiao J.-Y., Wang J.-X., Li X.-W., Cui Z., Gao J. Prognostic Value of Metabolic Syndrome in Patients With Non-ST Elevated Myocardial Infarction Undergoing Percutaneous Coronary Intervention. Frontiers in Cardiovascular Medicine 2022; 9(June): 1–10. doi:10.3389/fcvm.2022.912999.

18. Ermolenko E., Simanenkova A., Voropaeva L., Lavrenova N., Kotyleva M., Minasian S., Chernikova A., Timkina N., Gladyshev N., Dmitriev A., et al. Metformin Influence on the Intestinal Microbiota and Organism of Rats with Metabolic Syndrome. International Journal of Molecular Sciences 2022; 23(12): 6837. doi:10.3390/ijms23126837.

19. Simanenkova A., Minasian S., Karonova T., Vlasov T., Timkina N., Shpilevaya O., Khalzova A., Shimshilashvili A., Timofeeva V., Samsonov D., et al. Comparative evaluation of metformin and liraglutide cardioprotective effect in rats with impaired glucose tolerance. Scientific Reports 2021; 11(1): 6700. doi:10.1038/s41598-021-86132-2.

20. Chandra L., Pandey S., Baral N., Majhi S., Acharya P., Karki P., Shrestha S., Das B. Prevalence of the metabolic syndrome in acute myocardial infarction and its impact on hospital outcomes. International Journal of Diabetes in Developing Countries 2009; 29(2): 52. doi:10.4103/0973-3930.53120.

21. Hohendanner F., Boegner M., Huettemeister J., Zhang K., Dreysse S., Knosalla C., Falk V., Schoenrath F., Just I.A., Stawowy P. Microvascular dysfunction in heart transplantation is associated with altered cardiomyocyte mitochondrial structure and unimpaired excitation-contraction coupling. PLOS ONE 2024; 19(5): e0303540. doi:10.1371/journal.pone.0303540.

22. Akande O., Chen Q., Toldo S., Lesnefsky E.J., Quader M. Ischemia and reperfusion injury to mitochondria and cardiac function in donation after circulatory death hearts - an experimental study. PLOS ONE 2020; 15(12): e0243504. doi:10.1371/journal.pone.0243504.

23. Schneeberger S., Amberger A., Mandl J., Hautz T., Renz O., Obrist P., Meusburger H., Brandacher G., Mark W., Strobl D., et al. Cold ischemia contributes to the development of chronic rejection and mitochondrial injury after cardiac transplantation. Transplant International 2010; 23(12): 1282–92. doi:10.1111/j.1432-2277.2010.01126.x.

24. Rukavina-Mikusic I.A., Rey M., Martinefski M., Tripodi V., Valdez L.B. Temporal evolution of cardiac mitochondrial dysfunction in a type 1 diabetes model. Mitochondrial complex I impairment, and H2O2 and NO productions as early subcellular events. Free Radical Biology and Medicine 2021; 162: 129–40. doi:10.1016/j.freeradbiomed.2020.11.033.

25. Cao L., Liu C., Ou C., Ma Q., Xu H., Li X., Bao Y., Chen R., Yang Y., Wu M., et al. Impact of pretransplant T2DM on left ventricular deformation and myocardial perfusion in heart transplanted recipients: a 3.0 T cardiac magnetic resonance study. Cardiovascular Diabetology 2024; 23(1): 216. doi:10.1186/s12933-024-02323-x.